Non-pheochromocytoma (PCC)/paraganglioma (PGL) tumors in patients with succinate dehydrogenase-related PCC-PGL syndromes: A clinicopathological and molecular analysis

European Journal of Endocrinology

Volumn 170, Issue 1, 2014, Pages 1-12

  Papathomas, Thomas G ^a   Gaal, Jose ^a   Corssmit, Eleonora P M ^b   Oudijk, Lindsey ^a   Korpershoek, Esther ^a   Heimdal, Ketil ^c   Bayley, Jean Pierre ^b   Morreau, Hans ^b   Van Dooren, Marieke ^d   Papaspyrou, Konstantinos ^e   Schreiner, Thomas ^f   Hansen, Torsten ^e   Andresen, Per Arne ^c   Restuccia, David F ^a   Van Kessel, Ingrid ^d   Van Leenders, Geert J L H ^a   Kros, Johan M ^a   Looijenga, Leendert H J ^a   Hofland, Leo J ^d   Mann, Wolf ^e   Van Nederveen, Francien H ^g   Mete, Ozgur ^h,i   Asa, Sylvia L ^h,i   De Krijger, Ronald R ^a,j   Dinjens, Winand N M ^a   more..

^a JOSEPHINE NEFKENS INSTITUTE   (Netherlands)

^b LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^c OSLO UNIVERSITY HOSPITAL   (Norway)

^d ERASMUS MEDICAL CENTER   (Netherlands)

^e UNIVERSITY MEDICAL CENTER MAINZ   (Germany)

^f OSLO UNIVERSITY HOSPITAL   (Norway)

^g Laboratory for Pathology   (Netherlands)

^h UNIVERSITY HEALTH NETWORK   (Canada)

ⁱ UNIVERSITY OF TORONTO   (Canada)

^j REINIER DE GRAAF HOSPITAL   (Netherlands)

more..

Author keywords

[No Author keywords available]

Indexed keywords

SUCCINATE DEHYDROGENASE;

ADENOMATOID TUMOR; ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; DISEASE ASSOCIATION; ENZYME ACTIVITY; ENZYME ASSAY; FEMALE; GENE FREQUENCY; GENE MUTATION; GENOTYPE PHENOTYPE CORRELATION; HETEROZYGOSITY LOSS; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; HYPOPHYSIS ADENOMA; IMMUNOHISTOCHEMISTRY; KIDNEY CARCINOMA; MALE; MEDICAL HISTORY; MIDDLE AGED; MOLECULAR PATHOLOGY; NEUROBLASTOMA; OUTCOME ASSESSMENT; PHEOCHROMOCYTOMA PARAGANGLIOMA SYNDROME; PRIORITY JOURNAL; PROTEIN EXPRESSION; SEMINOMA; SUCCINATE DEHYDROGENASE B GENE; SUCCINATE DEHYDROGENASE D GENE; SUCCINATE DEHYDROGENASE GENE; SYNDROME; THYROID CARCINOMA; TUMOR GENE; YOUNG ADULT;

ADENOMA; ADULT; CARCINOMA; CARCINOMA, PAPILLARY; CARCINOMA, RENAL CELL; EXONS; FEMALE; GENE DELETION; GERM-LINE MUTATION; HUMANS; LOSS OF HETEROZYGOSITY; MALE; MIDDLE AGED; MUTATION; NEOPLASM PROTEINS; PITUITARY NEOPLASMS; SUCCINATE DEHYDROGENASE; THYROID NEOPLASMS;

EID: 84890528424     PISSN: 08044643     EISSN: 1479683X     Source Type: Journal    
DOI: 10.1530/EJE-13-0623     Document Type: Article

References (66)

1. Papathomas TG, de Krijger RR & Tischler AS. Paragangliomas: update on differential diagnostic considerations, composite tumors and recent genetic developments. Seminars in Diagnostic Pathology 2013. In press. (doi:10.1053/j.semdp.2013.06.006)
2. Gill AJ. Succinate dehydrogenase (SDH) and mitochondrial driven neoplasia. Pathology 2012 44 285-292. (doi:10.1097/PAT.0b013e3283539932)
3. Barletta JA & Hornick JL. Succinate dehydrogenase-deficient tumors: diagnostic advances and clinical implications. Advances in Anatomic Pathology 2012 19 193-203. (doi:10.1097/PAP.0b013e31825c6bc6)
4. Ricketts CJ, Shuch B, Vocke CD, Metwalli AR, Bratslavsky G, Middelton L, Yang Y, Wei MH, Pautler SE, Peterson J et al. Succinate dehydrogenase kidney cancer: an aggressive example of the Warburg effect in cancer. Journal of Urology 2012 188 2063-2071. (doi:10.1016/j.juro.2012.08.030)
5. Denes J, Swords F, Xekouki P, Kumar AV, Maher ER, Wassif CA, Grieve NF, Baldeweg SE, Stratakis CA & Korbonits M. Familial pituitary adenoma and paraganglioma syndrome - a novel type of multiple endocrine neoplasia. Endocrine Reviews 2012 33 OR41-OR42.
6. Xekouki P, Pacak K, Almeida M, Wassif CA, Rustin P, Nesterova M, de la Luz Sierra M, Matro J, Ball E, Azevedo M et al. Succinate dehydrogenase (SDH) D subunit (SDHD) inactivation in a growth-hormone-producing pituitary tumor: a new association for SDH? Journal of Clinical Endocrinology and Metabolism 2012 97 E357-E366. (doi:10.1210/jc.2011-1179)
7. Dwight T, Mann K, Benn DE, Robinson BG, McKelvie P, Gill AJ, Winship I & Clifton-Bligh RJ. Familial SDHA mutation associated with pituitary adenoma and pheochromocytoma/paraganglioma. Journal of Clinical Endocrinology and Metabolism 2013 98 E1103-E1108. (doi:10.1210/jc.2013-1400)
8. Vanharanta S, Buchta M, McWhinney SR, Virta SK, Peçzkowska M, Morrison CD, Lehtonen R, Januszewicz A, Järvinen H, Juhola M et al. Early-onset renal cell carcinoma as a novel extraparaganglial component of SDHB-associated heritable paraganglioma. American Journal of Human Genetics 2004 74 153-159. (doi:10.1086/381054)
9. Oudijk L, Gaal J, Korpershoek E, van Nederveen FH, Kelly L, Schiavon G, Verweij J, Mathijssen RH, den Bakker MA, Oldenburg RA et al. SDHA mutations in adult and pediatric wild-type gastrointestinal stromal tumors. Modern Pathology 2013 26 456-463. (doi:10.1038/modpathol.2012.186)
10. van Hulsteijn LT, den Dulk AC, Hes FJ, Bayley JP, Jansen JC & Corssmit EP. No difference in phenotype of the main Dutch Sdhd founder mutations. Clinical Endocrinology 2013. In press. (doi:10.1111/cen.12223)
11. Gill AJ, Pachter NS, Chou A, Young B, Clarkson A, Tucker KM, Winship IM, Earls P, Benn DE, Robinson BG et al. Renal tumors associated with germline SDHB mutation show distinctive morphology. American Journal of Surgical Pathology 2011 35 1578-1585. (doi:10.1097/PAS.0b013e318227e7f4)
12. Limbach AL, Ni Y, Huang J, Eng C & Magi-Galluzzi C. Adenomatoid tumour of the adrenal gland in a patient with germline SDHD mutation: a case report and review of the literature. Pathology 2011 43 495-498. (doi:10.1097/PAT.0b013e3283486bb9)
13. Hes FJ, Weiss MM, Woortman SA, de Miranda NF, van Bunderen PA, Bonsing BA, Stokkel MP, Morreau H, Romijn JA, Jansen JC et al. Low penetrance of a SDHB mutation in a large Dutch paraganglioma family. BMC Medical Genetics 2010 11 92. (doi:10.1186/1471-2350-11-92)
14. Cascón A, Landa I, López-Jiménez E, Díez-Hernández A, Buchta M, Montero-Conde C, Leskelä S, Leandro-García LJ, Letón R, Rodríguez-Antona C et al. Molecular characterisation of a common SDHB deletion in paraganglioma patients. Journal of Medical Genetics 2008 45 233-238. (doi:10.1136/jmg.2007.054965)
15. Galera-Ruiz H, Gonzalez-Campora R, Rey-Barrera M, Rollón-Mayordomo A, Garcia-Escudero A, Fernández-Santos JM, DeMiguel M & Galera-Davidson H. W43X SDHD mutation in sporadic head and neck paraganglioma. Analytical and Quantitative Cytology and Histology 2008 30 119-123.
16. Solis DC, Burnichon N, Timmers HJ, Raygada MJ, Kozupa A, MerinoMJ, Makey D, Adams KT, Venisse A, Gimenez-Roqueplo AP et al. Penetrance and clinical consequences of a gross SDHB deletion in a large family. Clinical Genetics 2009 75 354-363. (doi:10.1111/j.1399-0004.2009.01157.x)
17. Zbuk KM, Patocs A, Shealy A, Sylvester H, Miesfeldt S & Eng C. Germline mutations in PTEN and SDHC in a woman with epithelial thyroid cancer and carotid paraganglioma. Nature Clinical Practice. Urology 2007 4 608-612. (doi:10.1038/ncponc0935)
18. Timmers HJ, Kozupa A, Eisenhofer G, Raygada M, Adams KT, Solis D, Lenders JW & Pacak K. Clinical presentations, biochemical phenotypes, and genotype-phenotype correlations in patients with succinate dehydrogenase subunit B-associated pheochromocytomas and paragangliomas. Journal of Clinical Endocrinology and Metabolism 2007 92 779-786. (doi:10.1210/jc.2006-2315)
19. Jasperson KW, Kohlmann W, Gammon A, Slack H, Buchmann L, Hunt J, Kirchhoff AC, Baskin H, Shaaban A & Schiffman JD. Role of rapid sequence whole-body MRI screening in SDH-associated hereditary paraganglioma families. Familial Cancer 2013. In press. (doi:10.1007/s10689-013-9639-6)
20. Malinoc A, Sullivan M, Wiech T, Schmid KW, Jilg C, Straeter J, Deger S, Hoffmann MM, Bosse A, Rasp G et al. Biallelic inactivation of the SDHC gene in renal carcinoma associated with paraganglioma syndrome type 3. Endocrine-Related Cancer 2012 19 283-290. (doi:10.1530/ERC-11-0324)
21. Housley SL, Lindsay RS, Young B, McConachie M, Mechan D, Baty D, Christie L, Rahilly M, Qureshi K & Fleming S. Renal carcinoma with giant mitochondria associated with germ-line mutation and somatic loss of the succinate dehydrogenase B gene. Histopathology 2010 56 405-408. (doi:10.1111/j.1365-2559.2010.03482.x)
22. Ricketts CJ, Forman JR, Rattenberry E, Bradshaw N, Lalloo F, Izatt L, Cole TR, Armstrong R, Kumar VK, Morrison PJ et al. Tumor risks and genotype-phenotype-proteotype analysis in 358 patients with germline mutations in SDHB and SDHD. Human Mutation 2010 31 41-51. (doi:10.1002/humu.21136)
23. Merino MJ, Parillar-Castella ER & Lineham M. The unrecognised morphology of renal tumours in SDH syndromes: immunohistochemistry and genetic changes. Modern Pathology 2010 23 (Supp 206A) 917 (abstract).
24. Linehan WM. Genetic basis of kidney cancer: role of genomics for the development of disease-based therapeutics. Genome Research 2012 22 2089-2100. (doi:10.1101/gr.131110.111)
25. Henderson A, Douglas F, Perros P, Morgan C & Maher ER. SDHB-associated renal oncocytoma suggests a broadening of the renal phenotype in hereditary paragangliomatosis. Familial Cancer 2009 8 257-260. (doi:10.1007/s10689-009-9234-z)
26. Said-Al-Naief N & Ojha J. Hereditary paraganglioma of the nasopharynx. Head and Neck Pathology 2008 2 272-278. (doi:10.1007/s12105-008- 0090-1)
27. Ricketts C, Woodward ER, Killick P, Morris MR, Astuti D, Latif F & Maher ER. Germline SDHB mutations and familial renal cell carcinoma. Journal of the National Cancer Institute 2008 100 1260-1262. (doi:10.1093/jnci/djn254)
28. Srirangalingam U, Khoo B, Walker L, MacDonald F, Skelly RH, George E, Spooner D, Johnston LB, Monson JP, Grossman AB et al. Contrasting clinical manifestations of SDHB and VHL associated chromaffin tumours. Endocrine-Related Cancer 2009 16 515-525. (doi:10.1677/ERC-08-0239)
29. Srirangalingam U, Walker L, Khoo B, MacDonald F, Gardner D, Wilkin TJ, Skelly RH, George E, Spooner D, Monson JP et al. Clinical manifestations of familial paraganglioma and phaeochromocytomas in succinate dehydrogenase B (SDH-B) gene mutation carriers. Clinical Endocrinology 2008 69 587-596. (doi:10.1111/j.1365-2265.2008.03274.x)
30. Tuthill M, Barod R, Pyle L, Cook T, Chew S, Gore M, Maxwell P & Eisen T. A report of succinate dehydrogenase B deficiency associated with metastatic papillary renal cell carcinoma: successful treatment with the multi-targeted tyrosine kinase inhibitor sunitinib. BMJ Case Reports 2009. (doi:10.1136/bcr.08. 2008.0732)
31. Gill AJ, Pachter NS, Clarkson A, Tucker KM, Winship IM, Benn DE, Robinson BG & Clifton-Bligh RJ. Renal tumors and hereditary pheochromocytoma- paraganglioma syndrome type 4. New England Journal of Medicine 2011 364 885-886. (doi:10.1056/NEJMc1012357)
32. Cascón A, Montero-Conde C, Ruiz-Llorente S, Mercadillo F, Letón R, Rodríguez-Antona C, Martínez-Delgado B, Delgado M, Díez A, Rovira A et al. Gross SDHB deletions in patients with paraganglioma detected by multiplex PCR: a possible hot spot? Genes, Chromosomes & Cancer 2006 45 213-219. (doi:10.1002/gcc.20283)
33. van Nederveen FH, Gaal J, Favier J, Korpershoek E, Oldenburg RA, de Bruyn EM, Sleddens HF, Derkx P, Rivière J, Dannenberg H et al. An immunohistochemical procedure to detect patients with paraganglioma and phaeochromocytoma with germline SDHB, SDHC, or SDHD gene mutations: a retrospective and prospective analysis. Lancet Oncology 2009 10 764-771. (doi:10.1016/S1470-2045(09)70164-0)
34. Papaspyrou K, Mewes T, Rossmann H, Fottner C, Schneider-Raetzke B, Bartsch O, Schreckenberger M, Lackner KJ, Amedee RG & Mann WJ. Head and neck paragangliomas: report of 175 patients (1989-2010). Head & Neck 2012 34 632-637. (doi:10.1002/hed.21790)
35. Neumann HP, Pawlu C, Peczkowska M, Bausch B, McWhinney SR, MuresanM, Buchta M, Franke G, Klisch J, Bley TA et al. Distinct clinical features of paraganglioma syndromes associated with SDHB and SDHD gene mutations. Journal of the American Medical Association 2004 292 943-951. (doi:10.1001/jama.292.8.943)
36. Opocher G & Schiavi F. Functional consequences of succinate dehydrogenase mutations. Endocrine Practice 2011 17 (Suppl 3) 64-71. (doi:10.4158/EP11070.RA)
37. Berger AH, Knudson AG & Pandolfi PP. A continuum model for tumour suppression. Nature 2011 476 163-169. (doi:10.1038/nature10275)
38. Grogan RH, Pacak K, Pasche L, Huynh TT & Greco RS. Bilateral adrenal medullary hyperplasia associated with an SDHB mutation. Journal of Clinical Oncology 2011 29 e200-e202. (doi:10.1200/JCO.2010.32.2156)
39. Weber A, Hoffmann MM, Neumann HP & Erlic Z. Somatic mutation analysis of the SDHB, SDHC, SDHD, and RET genes in the clinical assessment of sporadic and hereditary pheochromocytoma. Hormones & Cancer 2012 3 187-192. (doi:10.1007/s12672-012-0113-y)
40. Pasini B & Stratakis CA. SDH mutations in tumorigenesis and inherited endocrine tumours: lesson from the phaeochromocytoma-paraganglioma syndromes. Journal of Internal Medicine 2009 266 19-42. (doi:10.1111/j.1365-2796.2009. 02111.x)
41. Habano W, Sugai T, Nakamura S, Uesugi N, Higuchi T, Terashima M & Horiuchi S. Reduced expression and loss of heterozygosity of the SDHD gene in colorectal and gastric cancer. Oncology Reports 2003 10 1375-1380.
42. Bayley JP, van Minderhout I, Hogendoorn PC, Cornelisse CJ, van der Wal A, Prins FA, Teppema L, Dahan A, Devilee P & Taschner PE. Sdhd and Sdhd/H19 knockout mice do not develop paraganglioma or pheochromocytoma. PLoS ONE 2009 4 e7987. (doi:10.1371/journal.pone.0007987)
43. Piruat JI, Pintado CO, Ortega-Sáenz P, Roche M & López-Barneo J. The mitochondrial SDHD gene is required for early embryogenesis, and its partial deficiency results in persistent carotid body glomus cell activation with full responsiveness to hypoxia. Molecular and Cellular Biology 2004 24 10933-10940. (doi:10.1128/MCB.24.24.10933-10940.2004)
44. Efstathiadou ZA, Sapranidis M, Anagnostis P & Kita MD. An unusual case of Cowden-like syndrome, neck paraganglioma and pituitary adenoma. Head & Neck 2013. In press. (doi:10.1002/hed.23420)
45. Boguszewski CL, Fighera TM, Bornschein A, Marques FM, Dénes J, Rattenbery E, Maher ER, Stals K, Ellard S & Korbonits M. Genetic studies in a coexistence of acromegaly, pheochromocytoma, gastrointestinal stromal tumor (GIST) and thyroid follicular adenoma. Arquivos Brasileiros de Endocrinologia e Metabologia 2012 56 507-512. (doi:10.1590/S0004-27302012000800008)
46. Xekouki P & Stratakis CA. Succinate dehydrogenase (SDHx) mutations in pituitary tumors: could this be a new role for mitochondrial complex II and/or Krebs cycle defects? Endocrine-Related Cancer 2012 19 C33-C40. (doi:10.1530/ERC-12-0118)
47. Benn DE, Gimenez-Roqueplo AP, Reilly JR, Bertherat J, Burgess J, Byth K, Croxson M, Dahia PL, Elston M, Gimm O et al. Clinical presentation and penetrance of pheochromocytoma/paraganglioma syndromes. Journal of Clinical Endocrinology and Metabolism 2006 91 827-836. (doi:10.1210/jc.2005-1862)
48. Zantour B, Guilhaume B, Tissier F, Louvel A, Jeunemaitre X, Gimenez-Roqueplo AP & Bertagna X. A thyroid nodule revealing a paraganglioma in a patient with a new germline mutation in the succinate dehydrogenase B gene. European Journal of Endocrinology 2004 151 433-438. (doi:10.1530/eje.0. 1510433)
49. Siegel R, NaishadhamD & Jemal A. Cancer statistics, 2013. CA: A Cancer Journal for Clinicians 2013 63 11-30. (doi:10.3322/caac.21166)
50. Aschebrook-Kilfoy B, Kaplan EL, Chiu BC, Angelos P & Grogan RH. The acceleration in papillary thyroid cancer incidence rates is similar among racial and ethnic groups in the United States. Annals of Surgical Oncology 2013 20 2746-2753. (doi:10.1245/s10434-013-2892-y)
51. Ni Y, Zbuk KM, Sadler T, Patocs A, Lobo G, Edelman E, Platzer P, Orloff MS, Waite KA & Eng C. Germline mutations and variants in the succinate dehydrogenase genes in Cowden and Cowden-like syndromes. American Journal of Human Genetics 2008 83 261-268. (doi:10.1016/j.ajhg.2008.07.011)
52. Ni Y, He X, Chen J, Moline J, Mester J, Orloff MS, Ringel MD & Eng C. Germline SDHx variants modify breast and thyroid cancer risks in Cowden and Cowden-like syndrome via FAD/NAD-dependant destabilization of p53. Human Molecular Genetics 2012 21 300-310. (doi:10.1093/hmg/ddr459)
53. Bayley JP, Devilee P & Taschner PE. The SDH mutation database: an online resource for succinate dehydrogenase sequence variants involved in pheochromocytoma, paraganglioma and mitochondrial complex II deficiency. BMC Medical Genetics 2005 6 39. (doi:10.1186/1471-2350-6-39)
54. Schimke RN, Collins DL & Stolle CA. Paraganglioma, neuroblastoma, and a SDHB mutation: resolution of a 30-year-old mystery. American Journal of Medical Genetics. Part A 2010 152A 1531-1535. (doi:10.1002/ajmg.a.33384)
55. Miettinen M, Sarlomo-Rikala M, Cue PM, Czapiewski P, Langfort R, Waloszczyk P, Wazny K, Biernat W, Lasota J & Wang Z. Mapping of succinate dehydrogenase losses in 2258 epithelial neoplasms. Applied Immunohistochemistry & Molecular Morphology 2013.
56. Morris MR, Maina E, Morgan NV, Gentle D, Astuti D, Moch H, Kishida T, Yao M, Schraml P, Richards FM et al. Molecular genetic analysis of FIH-1, FH, and SDHB candidate tumour suppressor genes in renal cell carcinoma. Journal of Clinical Pathology 2004 57 706-711. (doi:10.1136/jcp.2003.011767)
57. Rapizzi E, Ercolino T, Canu L, Giaché V, Francalanci M, Pratesi C, Valeri A & Mannelli M. Mitochondrial function and content in pheochromocytoma/paraganglioma of succinate dehydrogenase mutation carriers. Endocrine-Related Cancer 2012 19 261-269. (doi:10.1530/ERC-11-0263)
58. Belinsky MG, Rink L, Flieder DB, Jahromi MS, Schiffman JD, Godwin AK & Mehren MV. Overexpression of insulin-like growth factor 1 receptor and frequent mutational inactivation of SDHA in wild-type SDHB-negative gastrointestinal stromal tumors. Genes, Chromosomes & Cancer 2013 52 214-224. (doi:10.1002/gcc.22023)
59. Kaelin WG Jr. The von Hippel-Lindau tumour suppressor protein: O2 sensing and cancer. Nature Reviews. Cancer 2008 8 865-873. (doi:10.1038/nrc2502)
60. Dahia PL, Ross KN, Wright ME, Hayashida CY, Santagata S, Barontini M, Kung AL, Sanso G, Powers JF, Tischler AS et al. A HIF1a regulatory loop links hypoxia and mitochondrial signals in pheochromocytomas. PLoS Genetics 2005 1 72-80. (doi:10.1371/journal.pgen.0010008)
61. Merlo A, de Quiros SB, Secades P, Zambrano I, Balbín M, Astudillo A, Scola B, Arístegui M, Suarez C & Chiara MD. Identification of a signaling axis HIF-1a/microRNA-210/ISCU independent of SDH mutation that defines a subgroup of head and neck paragangliomas. Journal of Clinical Endocrinology and Metabolism 2012 97 E2194-E2200. (doi:10.1210/jc.2012-2410)
62. Lehtonen HJ. Hereditary leiomyomatosis and renal cell cancer: update on clinical and molecular characteristics. Familial Cancer 2011 10 397-411. (doi:10.1007/s10689-011-9428-z)
63. Deyell RJ & Attiyeh EF. Advances in the understanding of constitutional and somatic genomic alterations in neuroblastoma. Cancer Genetics 2011 204 113-121. (doi:10.1016/j.cancergen.2011.03.001)
64. Son EJ & Nosé V. Familial follicular cell-derived thyroid carcinoma. Frontiers in Endocrinology 2012 3 61. (doi:10.3389/fendo.2012.00061)
65. Elston MS, McDonald KL, Clifton-Bligh RJ & Robinson BG. Familial pituitary tumor syndromes. Nature Reviews. Endocrinology 2009 5 453-461. (doi:10.1038/nrendo.2009.126)
66. Kratz CP, Mai PL & Greene MH. Familial testicular germ cell tumours. Best Practice & Research. Clinical Endocrinology & Metabolism 2010 24 503-513. (doi:10.1016/j.beem.2010.01.005)